Celyad Oncology Provides Updates on Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition
07. Dezember 2020 01:00 ET
|
Celyad SA
First patient dosed in the CYAD-211 Phase 1 IMMUNICY-1 trial. Preclinical results for CYAD-211 for multiple myeloma showed robust antitumor activity with no demonstrable evidence of Graft-versus-Host...
Celyad Oncology Announces Dosing of First Patient in Phase 1 IMMUNICY-1 Trial of CYAD-211 for Multiple Myeloma
04. Dezember 2020 01:00 ET
|
Celyad SA
Preliminary data from the Phase 1 trial are expected first half 2021Additional €3.4 million in non-dilutive funding from SPW-Recherche of the Walloon Region to support advancement of CYAD-211 ...
Celyad Oncology to Participate in a Fireside Chat at the JMP Securities Hematology Summit
01. Dezember 2020 16:01 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Announces Third Quarter 2020 Financial Results and Recent Business Highlights
10. November 2020 16:01 ET
|
Celyad SA
Established a clinical trial collaboration with MSD to evaluate CYAD-101 with KEYTRUDA® in patients with microsatellite stable mCRCExpect to initiate the expansion cohort of the Phase 1 alloSHRINK...
Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition
04. November 2020 16:01 ET
|
Celyad SA
Three accepted abstracts will be presented virtually in a pre-recorded poster session MONT-SAINT-GUIBERT, Belgium, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq:...
Celyad Oncology Announces November 2020 Investor Conference Schedule
02. November 2020 16:01 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 with KEYTRUDA® (pembrolizumab) in Patients with Microsatellite Stable mCRC
29. September 2020 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology to Participate in a Fireside Chat at the 7th Annual Jefferies Cell Therapy Summit
23. September 2020 16:01 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology to Host Virtual Research & Development Webinar on September 29
22. September 2020 16:01 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Establishes At-the-Market Facility
14. September 2020 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...